Levodopa–Entacapone–Carbidopa Intestinal Gel in advanced Parkinson’s disease: clinical positioning, candidate profiling, and implementation roadmap

Device-aided therapies (DATs) for Parkinson’s disease (PD) with motor complications encompass deep brain stimulation (DBS), intrajejunal and subcutaneous infusions. Levodopa-carbidopa-entacapone intestinal gel (LECIG) infusion is the most recent strategy to be included in the intrajejunal class. By adding peripheral catechol-O-methyltransferase (COMT) inhibition, LECIG increases levodopa bioavailability, enabling a comparable dopaminergic effect at a reduced levodopa dose and infusion volume. Drawing on the discussion of a national advisory board of Italian movement disorder specialists, this perspective addresses the positioning of LECIG in PD patients with motor fluctuations. LECIG broadens the intrajejunal infusion landscape with a smaller device and potential metabolic advantages related to reduced 3-O-methyldopa generation. Two candidate scenarios predominate: the patient requiring a first infusional DAT after failure of optimized oral therapy who is ineligible for or declines DBS, and the patient already on a DAT with residual or worsening/re-emergent fluctuations. Favorable selection features include a levodopa-responsive, motor-fluctuation-predominant phenotype, documented COMT-inhibitor tolerance, absence of overt dementia with adequate caregiver support, a rationale for levodopa dose sparing (e.g., peripheral neuropathy risk), and concomitant dysphagia that features an additional niche benefitting of intestinal therapies. Cautionary or unfavorable features include levodopa-resistant axial disability, severe cognitive impairment, absence of caregiver support, COMT-inhibitor intolerance, and active neuropsychiatric symptoms, other than gastrointestinal contraindication for receiving gastrojejunostomy. Implementation barriers include the need for structured gastroenterology collaboration, and a potential cost-per-quality-adjusted-life-year higher than comparator DATs. Precise, multidimensional patient selection, together with a prescribing roadmap, with prospective registries, and structured multidisciplinary agenda, could be the cornerstone of optimizing outcomes.

Authors

Institutions

Publication Details

Journal
Frontiers in Neurology
Published
2026-11-12
DOI
https://doi.org/10.3389/fneur.2026.2017429
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Levodopa–Entacapone–Carbidopa Intestinal Gel in advanced Parkinson’s disease: clinical positioning, candidate profiling, and implementation roadmap

Giulia Lazzeri, Francesco Cavallieri, Daniele Belvisi, Massimo Marano et al.
Frontiers in Neurology
Parkinson's Disease Mechanisms and Treatments
article

Levodopa–Entacapone–Carbidopa Intestinal Gel in advanced Parkinson’s disease: clinical positioning, candidate profiling, and implementation roadmap

Giulia Lazzeri, Francesco Cavallieri, Daniele Belvisi, Massimo Marano, Valentina Leta, Mario Meloni, Edoardo Bianchini, Pierluigi Tocco, Maria Chiara Malaguti, Carlo Alberto Artusi, Chiara Sorbera, Micol Avenali, Rosa De Micco
article en

Abstract

Device-aided therapies (DATs) for Parkinson’s disease (PD) with motor complications encompass deep brain stimulation (DBS), intrajejunal and subcutaneous infusions. Levodopa-carbidopa-entacapone intestinal gel (LECIG) infusion is the most recent strategy to be included in the intrajejunal class. By adding peripheral catechol-O-methyltransferase (COMT) inhibition, LECIG increases levodopa bioavailability, enabling a comparable dopaminergic effect at a reduced levodopa dose and infusion volume. Drawing on the discussion of a national advisory board of Italian movement disorder specialists, this perspective addresses the positioning of LECIG in PD patients with motor fluctuations. LECIG broadens the intrajejunal infusion landscape with a smaller device and potential metabolic advantages related to reduced 3-O-methyldopa generation. Two candidate scenarios predominate: the patient requiring a first infusional DAT after failure of optimized oral therapy who is ineligible for or declines DBS, and the patient already on a DAT with residual or worsening/re-emergent fluctuations. Favorable selection features include a levodopa-responsive, motor-fluctuation-predominant phenotype, documented COMT-inhibitor tolerance, absence of overt dementia with adequate caregiver support, a rationale for levodopa dose sparing (e.g., peripheral neuropathy risk), and concomitant dysphagia that features an additional niche benefitting of intestinal therapies. Cautionary or unfavorable features include levodopa-resistant axial disability, severe cognitive impairment, absence of caregiver support, COMT-inhibitor intolerance, and active neuropsychiatric symptoms, other than gastrointestinal contraindication for receiving gastrojejunostomy. Implementation barriers include the need for structured gastroenterology collaboration, and a potential cost-per-quality-adjusted-life-year higher than comparator DATs. Precise, multidimensional patient selection, together with a prescribing roadmap, with prospective registries, and structured multidisciplinary agenda, could be the cornerstone of optimizing outcomes.

Frontiers in NeurologyVol. 17
Institut polytechnique de Grenoble (FR), University of Verona (IT), Centre National de la Recherche Scientifique (FR), Università Campus Bio-Medico (IT), King's College London (GB), University of Campania "Luigi Vanvitelli" (IT), University of Pavia (IT), Istituto Neurologico Mediterraneo (IT), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Laboratoire d'Informatique de Grenoble (FR), Provincia Autonoma di Trento (IT), Azienda Ospedaliero-Universitaria Cagliari (IT), Campus Bio Medico University Hospital (IT), Azienda USL di Pescara (IT), Fondazione IRCCS Istituto Neurologico Carlo Besta (IT), Parkinson's Institute and Clinical Center (US), Sapienza University of Rome (IT)
Good health and well-being
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon